Update on anti-phospholipid antibodies in SLE: The Hopkins Lupus Cohort

Research output: Contribution to journalReview articlepeer-review

66 Scopus citations


Anti-phospholipid antibodies are common in patients in the Hopkins Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-β2-glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis.

Original languageEnglish (US)
Pages (from-to)419-423
Number of pages5
Issue number4
StatePublished - Apr 2010


  • Anti-cardiolipin antibodies
  • Anti-phospholipid syndrome
  • Lupus anticoagulant

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Update on anti-phospholipid antibodies in SLE: The Hopkins Lupus Cohort'. Together they form a unique fingerprint.

Cite this